Publications by authors named "Eugen Tausch"

42Publications

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Blood 2020 Sep 29. Epub 2020 Sep 29.

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020007039DOI Listing
September 2020

mutations in chronic lymphocytic leukemia - uncommon and unfavorable.

Haematologica 2020 31;105(2):255-256. Epub 2020 Jan 31.

Department of Internal Medicine III, Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.238691DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012489PMC
July 2020

Response to Comment by Jonathan Weiss

Haematologica 2019 11;104(11):e542

Internal Medicine III, Ulm University, Ulm. Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.236570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821624PMC
November 2019

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med 2019 Jun 4;380(23):2225-2236. Epub 2019 Jun 4.

From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1815281
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1815281DOI Listing
June 2019

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Haematologica 2016 Mar;101(3):263-5

Division of Experimental Oncology and Department of Onco-Hematology, Università Vita-Salute San Raffaele and IRCCS Instituto Scientifico San Raffaele, Milan, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.139246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815716PMC
March 2016

Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.

Oncol Res Treat 2016 26;39(1-2):34-40. Epub 2016 Jan 26.

Department of Internal Medicine III, Ulm University, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000443906DOI Listing
December 2016

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016

Advances in treating chronic lymphocytic leukemia.

F1000Prime Rep 2014 1;6:65. Epub 2014 Aug 1.

Ulm University, Department of Internal Medicine III Albert-Einstein-Allee 23, 89081 Ulm Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12703/P6-65DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126532PMC
August 2014